How a $10,000 Investment in Broadcom Under Hock Tan Grew to $3.2M

The market is still pricing AVGO as a semis winner, but the real mechanism is that it has become a toll road on hyperscaler capex. If AI orders keep converting, AVGO can compound earnings even if the broader chip cycle softens, which should preserve a premium multiple versus more cyclical large-cap semis. The second-order loser is the merchant accelerator ecosystem: every dollar of custom silicon content is a dollar less captured by general-purpose GPUs and some adjacent networking spend, while the second-order winners are the hyperscalers themselves, because lower compute cost improves AI ROI and can extend the capex runway for GOOGL and META.

That said, this is now a 3-6 month credibility trade on whether customer capex stays linear and whether backlog converts without digestion. The key falsifier is not one strong quarter; it is any sign that bookings-to-revenue conversion slows, or that hyperscaler capital budgets flatten into year-end planning. Succession is a longer-dated overhang, but near term the bigger risk is investors extrapolating a straight line from a few oversized design wins into a multi-year supercycle and paying for perfection before the cycle is fully visible.

From a trading standpoint, this looks better as a buy-the-dip name than a chase at elevated forward multiples. If the stock cannot hold the low-$370s after earnings, or if hyperscaler capex commentary weakens, the market will likely start discounting a 2027 digestion phase earlier than consensus expects. For now, the asymmetry still favors staying long, but with tighter entry discipline and a willingness to take profits into strength rather than underwriting a full-cycle narrative.